<DOC>
	<DOC>NCT02799550</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 19 (CD19)-directed chimeric antigen receptor modified T cells (CART-19) infusions in patients with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL)</brief_summary>
	<brief_title>Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL</brief_title>
	<detailed_description>The relapsed and/or refractory B-ALL patients will receive infusions of allogeneic CART-19 within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily vindesine, mitoxantrone, cyclophosphamide, pegaspargase and dexamethasone, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>Age ≥ 60 years Patient with relapsed and/or refractory CD19 positive Bcell acute lymphoblastic leukemia (BALL) Estimated life expectancy ≥ 12 weeks (according to investigator's judgment) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Previous treatment with investigational gene or cell therapy medicine products CD19 negative Bcell leukemia Any uncontrolled active medical disorder that would preclude participation as outlined</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CART</keyword>
	<keyword>ALL</keyword>
	<keyword>elderly</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>CD19+</keyword>
</DOC>